|
ECAT DEVELOPMENT CAPITAL LIMITED 2002-10-03 ASX-SIGNAL-G HOMEX - Perth +++++++++++++++++++++++++ The Board of ECAT Development Capital Limited is pleased to announce that Clinical Cell Culture Pty Ltd ("C3") has reached an agreement to collaborate with Integra Life Sciences Corporation on research with C3`s ReCell(R) kits. The attached press release dated 3 October 2002 provides further in formation on the collaborative agreement. ECAT currently holds a 35.2% interest in Clinical Cell Culture Pty Ltd ("C3") and recently despatched a notice meeting and information memorandum to shareholders setting out, amongst other things, a proposal for the acquisition of 100% of C3. For more information visit the ECAT website at www.ecatdc.com.au Or alternatively contact: - Philip Rees (INVESTMENT MANAGER) on (08) 9355 6201. Alec Pismiris COMPANY SECRETARY (08) 9481 3733 MEDIA RELEASE NOVEL USE FOR RECELL(R) KITS IN MAJOR BURNS Australian biomedical company, Clinical Cell Culture Pty Ltd (C3), today announced they it has agreed to collaborate with Integra LifeSciences Corporation (Nasdaq: IART), Plainsboro, NJ in the United States, on research with C3`s ReCell(R) Kits. The research commenced recently with a pre-clinical evaluation which is designed to determine the potential benefit of using epidermal skin replacement techniques with C3`s ReCell(R) kits in combination with INTEGRA(R), Dermal Regeneration Template, to improve the treatment of severe burns and scar contractures. Fiona Wood, Chief Executive Officer of C3 and a specialist plastic and burns surgeon said C3 was encouraged by Integra Life Sciences` interest in the C3`s skin replacement technology. "ReCell(R) and INTEGRA(R) Template are complementary products when used individually in the treatment of burns and scar contractures, but the potential to use them together in a one step process is very exciting," Dr Wood said. "Severe burns often result in full thickness skin loss involving both the outer epidermal and second dermal layers which need to be replaced quickly to ensure survival. The goal of this collaboration is to determine if improved epithelialisation can occur using C3`s ReCell(R) Kits with INTEGRA(R)Template compared to existing treatment protocols. "Any new treatment that comes out of this research could represent a major advance in the life saving treatment of major burns victims." C3`s chief scientific officer, Marie Stoner, is assisting with the ongoing preliminary evaluation to test specific combinations of the two products in the United States. Following the tests, the outcomes will be evaluated and a future path for collaboration between the two companies will be determined. ABOUT THE PRODUCTS ReCell(R) (autologous cell harvesting kit) is a self-contained kit that can be used to harvest and prepare the patient`s own epidermal cells for reapplication to the wound site within 30 minutes, Surgeons ran use ReCell(R) to prepare enough cells to treat an area of approximately two per cent of an adult patient`s body surface area, which is equal to the size of two adult hands. ReCell(R) is not yet commercially available pending ongoing clinical trials and submissions for regulatory approvals. INTEGRA(R) Dermal Regeneration Template consists of two layers, a thin collagen- glycosaminoglycan matrix and a silicone membrane. This bi-layer skin replacement system is designed to provide immediate wound closure and permanent regeneration of dermis. After the patient`s dermis is regenerated, the surgeon removes the silicone outer layer and replace`s it with a thin epidermal autograft. INTEGRA(R) Template was developed for the treatment of life-threatening thermal injuries where sufficient autograft is not available at the time. First approved in the US in 1996, Integra has been used in more than 10,000 patients worldwide. Human skin consists of an outer layer (epidermis) and a second layer (dermis). The epidermis serves as a protective seal for the body, and the dermis provides structural strength and flexibility and supports the viability of the epidermis through a vascular network. ABOUT C3 C3 is a privately owned biomedical company, which develops and distributes tissue-engineered cellular products for autologous skin replacement. The company`s lead products and product candidates are CellSpray(R), cultured epithelial autograft spray suspension for the treatment of major burns, ReCell(R) autologous cell harvesting kit for the treatment of small burns, pigment loss and scars and EpiGrow(R) autologous epidermal derived fluid for the treatment of chronic wounds. Established in 1999, C3 was formed to commercialise products under licence from the McComb Foundation to advance the research undertaken by Fiona Wood and Marie Stoner into skin culture technologies. C3 is based in Perth, Western Australia and provides a worldwide service from its dedicated skin culture laboratory. C3`s major shareholder is ECAT Development Capital Limited, which has subscribed for 35% of its issued capital. ECAT shareholders will vote on a proposal to acquire C3 on October 25, 2002 that, if approved, would see C3 become a wholly owned subsidiary of ECAT. For further information please contact: Phil Rees or Maree Pickens Clinical Cell Culture Ph: +61 (0)8 9355 6288 or Paul Downie Porter Novelli Ph: +61 (0)8 9386 1233 Mobile: +61 (0)414 947 129 pdownie@wa.porternovelli.com.au Ein heutiger Anstieg in Australien um 17,6% bei 8,466,832 Aktien Umsatz. Grüsse |
|
| aus der Diskussion: | ECAT |
| Autor (Datum des Eintrages): | Geldhahn (03.10.02 07:28:09) |
| Beitrag: | 1 von 1 (ID:7507860) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |